Trial record 2 of 3 for:    msc-ntf

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS (NurOwn)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Brainstorm-Cell Therapeutics
Sponsor:
Information provided by (Responsible Party):
Brainstorm-Cell Therapeutics
ClinicalTrials.gov Identifier:
NCT02017912
First received: December 17, 2013
Last updated: August 13, 2014
Last verified: December 2013
  Purpose

This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in patients with ALS .

MSC-NTF cells are a novel cell-therapeutic approach which is expected to effectively deliver Neurotrophic factors, which are potent survival factors for neurons, directly to the site of damage.


Condition Intervention Phase
Amyotrophic Lateral Sclerosis (ALS)
Biological: Autologous MSC-NTF cells
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS

Resource links provided by NLM:


Further study details as provided by Brainstorm-Cell Therapeutics:

Primary Outcome Measures:
  • Number of patients with adverse events [ Time Frame: At all study visits: Visit 1 through visit 10 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation. [ Time Frame: At all study visits: Visit 1 through visit 10 ] [ Designated as safety issue: No ]
  • Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation [ Time Frame: Visits 1,2,3,5,6,7,8,9,10 ] [ Designated as safety issue: No ]

Estimated Enrollment: 48
Study Start Date: May 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Autologous MSC-NTF cells
Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
Biological: Autologous MSC-NTF cells
Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
Other Name: NurOwn
Placebo Comparator: Excipient
Combined intramuscular and intrathecal placebo administration

Detailed Description:

The MSC-NTF cell therapy (NurOwn™) is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patients' own bone marrow, propagated ex vivo and induced to secrete NTFs. The autologous MSC-NTF cells are back-transplanted into the ALS patient into the sites of damage, the spinal cord and the muscles.

NTFs are potent survival factors for embryonic, neonatal, and adult neurons and are considered potential therapeutic candidates for ALS. Delivery of appropriate NTFs to the immediate environment of afflicted neurons in ALS patients is expected to improve their survival and thus slow down disease progression and alleviate symptoms.

Previous open-label clinical trials have shown that MSC-NTF cells treatment was well tolerated and appears to be generally safe. Some initials indications of clinical benefit were also observed in some patients.

This multi-center, randomized, double blind, placebo controlled study will evaluate the safety and efficacy of a single combined intramuscular and intrathecal administration of MSC-NTF cells in early-stage ALS patients. Patients will be followed for approximately three months before transplantation with their autologous MSC-NTF cells or placebo. During this period of time, patient bone-marrow will be harvested and mesenchymal stromal cells will be isolated and expanded. Following treatment patients will be followed for a total of six months at monthly visits.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females ages 18 to 75 years old, inclusive.
  2. ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.
  3. Disease symptom onset ≤ 24 months, as determined by the first reported occurrence of symptomatic weakness of a limb or of spasticity, and ALSFRS-R ≥30 at the Screening Visit.
  4. Upright slow vital capacity (SVC) measure ≥65% of predicted for gender, height, and age at the Screening Visit.
  5. Subjects must be taking a stable dose of Riluzole for at least 30 days prior to enrollment or not be on Riluzole, and not have been on it for at least 30 days prior to enrollment (Riluzole-naïve subjects are permitted in the study).
  6. Capable of providing informed consent and willing and able to follow study procedures, including willingness to undergo lumbar puncture.
  7. Geographic accessibility to the study site and willingness and ability to comply with follow-up.
  8. Women of child-bearing potential must agree not to become pregnant for the duration of the study. Women must be willing to consistently use two forms of contraceptive therapy throughout the course of the trial, and undergo a pregnancy test one week before bone marrow aspiration. Men must be willing to consistently use two forms of contraceptive if their partners are of child-bearing age.
  9. Citizen or permanent resident of the United States.
  10. History of a chronic onset of a progressive motor weakness of greater than one year, but less than two years duration

Exclusion Criteria:

  1. Prior stem cell therapy of any kind.
  2. Inability to lie flat for the duration of intrathecal cell transplantation and/or bone marrow biopsy, or inability to tolerate study procedures for any other reason.
  3. History of autoimmune disease, myelodysplastic or myeloproliferative disorder, leukemia or lymphoma, whole body irradiation, hip fracture, or severe scoliosis.
  4. Any unstable clinically significant medical condition other than ALS (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure), treatment with anticoagulants that, in the opinion of the investigator, would compromise the safety of patients.
  5. Any history of malignancy including any malignancy affecting the central nervous system and melanoma, within the previous 5 years, with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline).
  6. Serum AST or ALT value >3.0 times the upper normal limit.
  7. Serum creatinine value >2.0 times the upper normal limit.
  8. Positive test for Hepatitis B, Hepatitis C, HIV.
  9. Current use of immunosuppressant medication or use of such medication within 4 weeks of Screening visit (Visit 1).
  10. Any history of acquired or inherited immune deficiency syndrome.
  11. Exposure to any other experimental agent (off-label use or investigational) or participation in a clinical trial within 30 days prior to Screening Visit (Visit 1).
  12. Use of non-invasive ventilation (NIV) or invasive ventilation (tracheostomy).
  13. Any history of either substance abuse within the past year, or unstable psychiatric disease according to PI judgment.
  14. Placement or usage of feeding tube
  15. Pregnant women or women currently breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02017912

Locations
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Melissa K Arnold       MKARNOLD@PARTNERS.ORG   
Principal Investigator: Merit Cudkowicz, MD         
Sub-Investigator: James D Berry, MD         
UMass Medical School Recruiting
Worcester, Massachusetts, United States, 01655
Contact: Diane McKenna-Yasek, RN, BSN       diane.mckenna-yasek@umassmed.edu   
Principal Investigator: Robert H Brown, D.Phil., M.D         
United States, Minnesota
Mayo Clinic Not yet recruiting
Rochester, Minnesota, United States, 55905
Contact: Pamela Vicari, RN    507-284-2676    rstalsresearch@mayo.edu   
Principal Investigator: Anthony J Windebank, MD         
Sponsors and Collaborators
Brainstorm-Cell Therapeutics
Investigators
Principal Investigator: Merit Cudkowicz, MD Massachusetts General Hospital
Principal Investigator: Robert H Brown, D.Phil, M.D. UMass Medical School
Principal Investigator: Anthony J. Windebank, M.D. Mayo Clinic
  More Information

No publications provided

Responsible Party: Brainstorm-Cell Therapeutics
ClinicalTrials.gov Identifier: NCT02017912     History of Changes
Other Study ID Numbers: BCT-001-US
Study First Received: December 17, 2013
Last Updated: August 13, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Brainstorm-Cell Therapeutics:
Mesenchymal Stromal cells
MSC-NTF
Cell therapy
ALS

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Sclerosis
Motor Neuron Disease
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
TDP-43 Proteinopathies
Neuromuscular Diseases
Proteostasis Deficiencies
Metabolic Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on September 11, 2014